Integrated QSAR, docking, pharmacokinetics, and molecular dynamics approaches for designing IRAK4 inhibitors against MYD88^L265P-driven diffuse large B-cell lymphoma
2025Discover Chemistry.JournalOpen access
10.1007/s44371-025-00391-wFull text3 citations